Astellas U.S. Unit Settles Off-Label Pediatric Use Case For $7.3 Million
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma, the U.S. unit of the Japan-based drug maker, has agreed to pay a $7.3 million fine for promoting pediatric use of its Mycamine (mycafungin) drug for treating invasive fungal infections.